• Alzinova completed a research study with Amsterdam UMC in its blood-based Alzheimer’s diagnostic program; results have now been presented.
• Findings supported earlier observations, showing a detectable antibody signal in serum with lower reactivity in Alzheimer’s patients versus controls.
• Work now shifts to assay optimization, followed by testing the updated method in a larger independent clinical cohort.
• Readout strengthens ongoing partnership talks, aligned with a previously announced plan to assess broader collaboration under a Fujirebio letter of intent.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzinova AB published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.